glucagon agonist retatrutide Retatrutide, a GIP, GLP-1 and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

If you are not already eating a fiber-rich diet, increase gradually over 2 to 3 weeks while your gut microbiome adjusts

In addition to dry mouth, these can include: Diarrhea or constipation Abdominal discomfort Gallbladder problems Low blood sugar (hypoglycemia) Pancreatitis Kidney problems That said, semaglutide does not tend to cause significant long-term side effects for most people with diabetes

INCRELEX is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids

Retrieved February 4, 2025